Home
>
US Stocks
>
NURIX THERAPEUTICS INC

NURIX THERAPEUTICS INC (NRIX)

$10.92

+0.75

(+7.37%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on NURIX THERAPEUTICS INC

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 6.78M → 12.68M (in $), with an average increase of 46.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -46.71M → -40.73M (in $), with an average increase of 14.7% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 36.3%

Performance

  • $10.14
    $11.06
    $10.92
    downward going graph

    7.14%

    Downside

    Day's Volatility :8.32%

    Upside

    1.27%

    downward going graph
  • $8.34
    $19.91
    $10.92
    downward going graph

    23.63%

    Downside

    52 Weeks Volatility :58.11%

    Upside

    45.15%

    downward going graph

Returns

PeriodNURIX THERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
21.87%
0.9%
-8.3%
6 Months
-11.79%
-6.8%
-6.5%
1 Year
3.12%
0.4%
-6.1%
3 Years
-42.56%
28.3%
21.8%

Highlights

Market Capitalization
482.5M
Book Value
$5.78
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.53
Wall Street Target Price
28.27
Profit Margin
0.0%
Operating Margin TTM
-441.52%
Return On Assets TTM
-28.48%
Return On Equity TTM
-61.58%
Revenue TTM
41.7M
Revenue Per Share TTM
0.82
Quarterly Revenue Growth YOY
31.8%
Gross Profit TTM
-145.9M
EBITDA
-179.2M
Diluted Eps TTM
-3.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.04
EPS Estimate Next Year
-3.39
EPS Estimate Current Quarter
-0.87
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    89%Buy
    10%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for NURIX THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
15
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 158.88%

Current $10.92
Target $28.27

Company Financials

FY18Y/Y Change
Revenue
37.4M
-
Net Income
-9.4M
-
Net Profit Margin
-25.18%
-
FY19Y/Y Change
Revenue
31.1M
↓ 16.91%
Net Income
-21.7M
↑ 130.15%
Net Profit Margin
-69.74%
↓ 44.56%
FY20Y/Y Change
Revenue
17.8M
↓ 42.73%
Net Income
-43.2M
↑ 99.28%
Net Profit Margin
-242.66%
↓ 172.92%
FY21Y/Y Change
Revenue
29.8M
↑ 66.95%
Net Income
-117.2M
↑ 171.02%
Net Profit Margin
-393.93%
↓ 151.27%
FY22Y/Y Change
Revenue
38.6M
↑ 29.84%
Net Income
-180.4M
↑ 53.9%
Net Profit Margin
-466.93%
↓ 73.0%
Q4 FY21Q/Q Change
Revenue
7.4M
↓ 27.86%
Net Income
-37.7M
↑ 30.75%
Net Profit Margin
-509.76%
↓ 228.5%
Q1 FY22Q/Q Change
Revenue
9.6M
↑ 30.08%
Net Income
-42.5M
↑ 12.81%
Net Profit Margin
-442.09%
↑ 67.67%
Q2 FY22Q/Q Change
Revenue
11.4M
↑ 18.82%
Net Income
-45.4M
↑ 6.74%
Net Profit Margin
-397.14%
↑ 44.95%
Q3 FY22Q/Q Change
Revenue
10.8M
↓ 5.61%
Net Income
-45.7M
↑ 0.68%
Net Profit Margin
-423.58%
↓ 26.44%
Q4 FY22Q/Q Change
Revenue
6.8M
↓ 37.14%
Net Income
-46.7M
↑ 2.21%
Net Profit Margin
-688.74%
↓ 265.16%
Q1 FY23Q/Q Change
Revenue
12.7M
↑ 87.01%
Net Income
-40.7M
↓ 12.81%
Net Profit Margin
-321.11%
↑ 367.63%
FY18Y/Y Change
Total Assets
45.4M
-
Total Liabilities
82.2M
-
FY19Y/Y Change
Total Assets
44.0M
↓ 2.97%
Total Liabilities
101.8M
↑ 23.73%
FY20Y/Y Change
Total Assets
396.3M
↑ 799.8%
Total Liabilities
106.1M
↑ 4.24%
FY21Y/Y Change
Total Assets
476.8M
↑ 20.29%
Total Liabilities
134.5M
↑ 26.77%
FY22Y/Y Change
Total Assets
416.8M
↓ 12.59%
Total Liabilities
113.1M
↓ 15.92%
Q4 FY21Q/Q Change
Total Assets
476.8M
↓ 3.31%
Total Liabilities
134.5M
↑ 14.1%
Q1 FY22Q/Q Change
Total Assets
437.7M
↓ 8.19%
Total Liabilities
131.8M
↓ 1.98%
Q2 FY22Q/Q Change
Total Assets
394.3M
↓ 9.92%
Total Liabilities
127.6M
↓ 3.21%
Q3 FY22Q/Q Change
Total Assets
459.3M
↑ 16.49%
Total Liabilities
116.8M
↓ 8.45%
Q4 FY22Q/Q Change
Total Assets
416.8M
↓ 9.27%
Total Liabilities
113.1M
↓ 3.19%
Q1 FY23Q/Q Change
Total Assets
370.2M
↓ 11.18%
Total Liabilities
96.1M
↓ 15.0%
FY18Y/Y Change
Operating Cash Flow
-31.7M
-
Investing Cash Flow
40.0M
-
Financing Cash Flow
529.0K
-
FY19Y/Y Change
Operating Cash Flow
601.0K
↓ 101.9%
Investing Cash Flow
8.5M
↓ 78.75%
Financing Cash Flow
126.0K
↓ 76.18%
FY20Y/Y Change
Operating Cash Flow
-80.0K
↓ 113.31%
Investing Cash Flow
-254.4M
↓ 3093.69%
Financing Cash Flow
339.0M
↑ 268966.67%
FY21Y/Y Change
Operating Cash Flow
-84.4M
↑ 105356.25%
Investing Cash Flow
-108.3M
↓ 57.45%
Financing Cash Flow
153.9M
↓ 54.61%
FY22Y/Y Change
Operating Cash Flow
-159.8M
↑ 89.42%
Investing Cash Flow
27.2M
↓ 125.12%
Financing Cash Flow
117.2M
↓ 23.84%
Q4 FY21Q/Q Change
Operating Cash Flow
-30.9M
↑ 3.13%
Investing Cash Flow
-36.5M
↑ 198.61%
Financing Cash Flow
500.0K
↓ 67.78%
Q1 FY22Q/Q Change
Operating Cash Flow
-42.6M
↑ 37.91%
Investing Cash Flow
40.0M
↓ 209.6%
Financing Cash Flow
1.5M
↑ 197.6%
Q2 FY22Q/Q Change
Operating Cash Flow
-32.9M
↓ 22.79%
Investing Cash Flow
-4.8M
↓ 111.9%
Financing Cash Flow
432.0K
↓ 70.97%
Q3 FY22Q/Q Change
Operating Cash Flow
-88.9M
↑ 170.21%
Investing Cash Flow
-63.1M
↑ 1223.74%
Financing Cash Flow
116.9M
↑ 26959.03%

Technicals Summary

Sell

Neutral

Buy

NURIX THERAPEUTICS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
15.68%
-11.79%
3.12%
-42.56%
-42.56%
Moderna, Inc.
Moderna, Inc.
-2.84%
-25.82%
-6.78%
115.4%
601.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.85%
-2.05%
21.5%
23.63%
137.1%
Seagen, Inc.
Seagen, Inc.
-1.57%
61.18%
37.09%
29.88%
217.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.7%
5.09%
24.54%
22.34%
123.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
NA
NA
NA
-3.04
-0.62
-0.28
0.0
5.78
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
Buy
$482.5M
-42.56%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
601.67%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
137.1%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
217.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
123.04%
26.18
35.4%

Institutional Holdings

  • BlackRock Inc

    8.73%

  • Baker Bros Advisors LP

    8.18%

  • Wasatch Advisors Inc.

    6.69%

  • Deep Track Capital, LP

    6.32%

  • Redmile Group, LLC

    5.79%

  • Vanguard Group Inc

    5.53%

Corporate Announcements

  • NURIX THERAPEUTICS INC Earnings

    NURIX THERAPEUTICS INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Organization
NURIX THERAPEUTICS INC
Employees
297
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs